Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

View:
Post by WarrantOfficer on Sep 05, 2024 12:37pm

Management

Formulation work for the five remaining products is complete a year after the PR on 14 Spet 2023 stating customers wanted a full line of products.....I know the pace in medical development can be slow. Clinical trials another two months to complete, it will take longer. 

The order page on the website gives you the impression that the entire product line is currently avavilable, when in fact it cannot be, as stated by todays PR. I phoned the 1-877-398-6866 order number,  a prerecorded message is played that does not even pronounce the name of the company properly or coherently. There is no-one to answer the call, it goes to a voice mail box, which makes sense as it seems there is currently zero products for sale. Why have the illlusion of products for sale?

Back to the prerecorded message stating the companies name in an unrecognizable manner, IMO indicates, and I keep sharing this time and time again,  management needs a shake up.
Comment by oldtrouf on Sep 05, 2024 1:42pm
Go to the Health Canada drug approval website and do a search for any product related to this company.  Nothing there.  What is going on here?
Comment by lscfa on Sep 05, 2024 7:00pm
incompetent bashing....https://health-products.canada.ca/lnhpd-bdpsnh/search-recherche  
Comment by lscfa on Sep 05, 2024 7:14pm
See screenshot....
Comment by postie1 on Sep 05, 2024 8:03pm
Count them. there are 6. bashers should try to put facts forward
Comment by biggdogg on Sep 05, 2024 3:46pm
I tried the number too, its SNAFU.  The only positive I see is they made new drugs instead of bracco generics, this will be much better long term. They need sales asap.
Comment by postie1 on Sep 05, 2024 5:02pm
Yup, sales are what is going to drive the price. I think we all feel your pain WO but the trolls are not getting my shares cheap.
Comment by WarrantOfficer on Sep 06, 2024 9:19am
3.5 years is a long time to invest in waiting for these 6 formulations to be finalized. My shares will not come cheap also. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1